Azilsartan Medoxomil for Treating Hypertension - Clinical Implications of Recent Trials

Login or register to view PDF.
Abstract

Objective: To evaluate the efficacy, safety, and clinical role of azilsartan medoxomil, an angiotensin-II receptor blocker (ARB) that recently gained US Food and Drug Administration approval for lowering of blood pressure (BP) in patients with hypertension. Methods: A systematic review of the literature was performed through October 2011 using the keywords and medical subject headings azilsartan, azilsartan medoxomil, TAK-491, TAK-536, and Edarbi. Citations eligible for inclusion were in vitro or in vivo evaluations of azilsartan medoxomil with no restrictions on patient population or indication used. Data related to the patient populations and outcomes of interest were extracted from each citation. Results: Three trials are available in full publication form, with others available only as abstracts. Azilsartan medoxomil 40 mg and 80 mg daily significantly improves both systolic and diastolic BP from baseline compared with placebo, and the 80 mg dose has greater efficacy than other ARBs, including olmesartan 40 mg daily and valsartan 320 mg daily. Improvements in both 24-hour BP using ambulatory monitoring and clinic BPs, as well as a higher proportion of patients reaching goal, have been seen with azilsartan medoxomil. Additional information shows added BP lowering when azilsartan medoxomil is combined with chlorthalidone. Adverse events are similar with azilsartan medoxomil compared to other ARBs and include headache, dizziness, urinary tract infections, and fatigue. Conclusions: Azilsartan medoxomil is a safe and effective ARB with a unique pharmacologic profile compared with other agents, including slowed angiotensin-II type 1 (AT1) receptor dissociation rates and improved receptor specificity. Studies have shown azilsartan medoxomil 80 mg once daily to reduce BP to a greater extent than valsartan and olmesartan, with similar safety and tolerability.

Acknowledgments: Supported in part by funding from the National Institutes of Health R01 AG022092-06 (PI: Dr White).
Support: The publication costs of this article were supported by Takeda Pharmaceuticals North America. Takeda Pharmaceuticals North America has had no involvement in the content of this article beyond review for factual accuracy. William L Baker, PharmD, BCPS (AQ Cardiology), and William B White, MD, FACP, FAHA, FASH, were fully responsible for all content and editorial decisions and received no financial support or other form of compensation related to the development of the manuscript.

Disclosure
William L Baker, PharmD, BCPS (AQ Cardiology), has no conflicts of interest to declare. William B White, MD, FACP, FAHA, FASH, discloses that his division has received research funding from Takeda Global Research and Development, manufacturer of azilsartan medoxomil, between 2007 and 2009. He is a paid safety consultant to Takeda for chairing the adjudication committee of the febuxostat cardiovascular outcomes study. He chairs the steering committee of the Examination of cardiovascular outcomes: alogliptin versus standard of care in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE) trial assessing the cardiovascular safety of alogliptin.
Correspondence
William L Baker, PharmD, BCPS (AQ Cardiology), Assistant Professor of Pharmacy and Medicine, University of Connecticut Schools of Pharmacy and Medicine, 263 Farmington Avenue, MC2205, Farmington, CT 06030. E: wbaker@uchc.edu
Received date
15 November 2011
Accepted date
20 January 2012
Citation
US Cardiology Volume 9 - Issue 1 - Spring 2012;2012:9(1):16-21
Correspondence
William L Baker, PharmD, BCPS (AQ Cardiology), Assistant Professor of Pharmacy and Medicine, University of Connecticut Schools of Pharmacy and Medicine, 263 Farmington Avenue, MC2205, Farmington, CT 06030. E: wbaker@uchc.edu
Login or register to view complete article.

Vegan Heart – The Blog of Heather Shenkman MD, FACC

  • 28 October 2014
    Last week, I attended the annual meeting of the American College of Lifestyle Medicine.  Not only was it an opportunity to hear some of my...
  • 18 October 2014
    It's interesting what our sense of "normal" is.When I first meet a patient, I ask her about her diet.  A typical response is, "I eat normal."...

Partners